Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Akorn, Inc. (NASDAQ: AKRX) shares declined 6.66 percent to close at $24.10 a share Monday. The stock traded between $21.11 and $24.54 on volume 5.22 million shares traded. The company’s guidance of EPS in the range of $0.76 to $0.79 for the 2014 fell short of consensus estimates of $0.86. Shares of Akorn are down approximately 2.0 percent year-to-date.
Get more information on Akorn free access to the in-depth equity report at:
Celldex Therapeutics, Inc. (NASDAQ: CLDX) shares fell 10.06 percent to close at $26.28 a share Monday. The stock traded between $25.76 and $27.73 on volume 4.58 million shares traded. The company reported revenues were $0.6 million for the fourth quarter of 2013, a decrease of 85.0 percent when compared to a year ago. Shares of Celldex Therapeutics are up approximately 8.0 percent year-to-date.
Get more information on Celldex Therapeutics and free access to the in-depth equity report at:
Cooper Tire & Rubber Co. (NYSE: CTB) shares fell 7.31 percent to close at $23.01 a share Monday. The stock traded between $22.54 and $24.02 on volume of 4.25 million shares traded. The company reported net sales were $832.0 million for the third quarter of 2013, a decrease of $263.0 million when compared to a year ago. Shares of Cooper Tire & Rubber are down approximately 4.0 percent year-to-date.
Get more information on Cooper Tire & Rubber and free access to the in-depth equity report at:
NewLink Genetics Corp. (NASDAQ: NLNK) shares dropped 11.58 percent to close at $39.08 a share Monday. The stock traded between $38.30 and $42.64 on volume of 1.12 million shares traded. R.W. Baird’s analysts have recently downgraded the company’s rating to “neutral” from “outperform”. Shares of NewLink Genetics are up approximately 78.0 percent year-to-date.
Get more information on NewLink Genetics and free access to the in-depth equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Five Star Equities